Depemokimab Compared with Mepolizumab for Patients with EGPA on Standard of Care Therapy (OCEAN)

The purpose of this study is to learn more about eosinophilic granulomatosis with polyangiitis (EGPA) that returns (relapse) or has not responded to treatment, and if the investigational drug depemokimab can improve the disease. This study is being done to help determine if depemokimab is safe and how it works compared to mepolizumab. An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA) to treat EGPA. Depemokimab is being compared to mepolizumab, which is approved by the FDA to treat EGPA. We will use your personal health information, information from the tests and procedures done for the study, and information about how the study drug affects you to help determine if depemokimab is safe and effective in treating EGPA.

Study Duration: Approximately 1 year

Disease(s): Granulomatosis with Polyangiitis (GPA)